Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company had earlier announced about the approval received from the MHRA for Liraglutide
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Subscribe To Our Newsletter & Stay Updated